2007, Number 2
<< Back Next >>
Acta Med 2007; 5 (2)
Eosinophilic fasciitis. Report of a refractory case to the treatment with cyclosporin A and etanercept
Badía FJ, Arévalo MFG
Language: Spanish
References: 13
Page: 89-92
PDF size: 121.42 Kb.
ABSTRACT
Male patient 39 years old, who is being diagnosticated clinicaly and histopathologicaly of Eosinophilic Fasciitis with 3 months of evolution; his treatment began with prednisone 30 mg/d with relative advance, after a month and half, colchicine 1 mg/d and cyclosporine-A 200 mg/d are added, the last one was removed after 6 months as it was ineffective. Afterwards due to an exacerbation of symptoms, a therapeutic test begins with etanercept 25 mg given twice weekly as a subcutaneous injection, for five months without any benefit shown. After 29 months of evolution, last 8 without treatment, the cutaneous manifestation have diminished partially but melanosis, poikiloderma and dyskeratosis chances where shown; besides that, there is approximately 70% of recuperation in secondary articular limitation to the dermis tension. It is concluded that neither the cyclosporine-A treatment or etanercept, at the used dose, were capable to modify the natural clinical course of the sickness in this case.
REFERENCES
Shulman LE. Diffuse fasciitis with hypergammaglobulinemia and eosinophilia: a new syndrome? J Rheumatol 1974; Suppl 1: 46.
Rodnan GP, DiBartolomeo A, Medsger TA Jr. Eosinophilic fasciitis. Report of six cases of newly recognized scleroderma-like syndrome (abstract). Arthritis Rheum 1975; 18: 525.
Barnes I, Rodnan GP, Medsger TA, Short D. Eosinophilic fasciitis. A pathological study of twenty cases. Am J Pathol 1979; 96: 493-507.
Seibold JR, Rodnan GP, Medsger TA, Winkelstein A. Circulating immune complexes in eosinophilic fasciitis. Arthritis Rheum 1982; 25: 1180-1185.
Janin A, Socie G, Devergie A, Aractingi S, Esperon H, Verola O et al. Fasciitis in chronic graft-versus-host disease-a clinicopathologic study of 14 cases. Ann Intern Med 1994; 120: 993-998.
Toquet C, Hamidou MA, Renaudin K, Jarry A, Foulc P, Barbarot S et al. In situ immunophenotype of the inflammatory infiltrate in eosinophilic fasciitis. J Rheumatol 2003; 30: 1811-1815.
Shakoory B, Fistzgerald SM, Lee SA, Chi DS, Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res 2004; 24(5): 271-281.
Varga L, Veli-Matti K. Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders. Curr Opin Rheumatol 1997; 9: 562-570.
Valencia IC, Chang A, Kirsner RS, Kerdel FA. Eosinophilic fasciitis responsive to treatment with pulsed steroid and cyclosporine. Int J Dermatol 1999; 38: 369-372.
Bukiej A, Dropinski J, Dyduch G, Szczeklik A. Eosinophilic fasciitis successfully treated with cyclosporine. Clin Rheumatol 2005; 24(6): 634-636.
Jaimes-Hernández J, Meléndez-Mercado C, Hernández-Díaz C. Fascitis eosinofílica, respuesta favorable con ciclosporina A. Primer Congreso Mexicano Canadiense de Reumatología. Reumatol Clin 2006; 2(1): 61.
Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 2003; 7(5): 382-386.
Trallero-Araguas E, Selva O-Callaghan A, Simeón-Aznar CP, Sanjurjo-Golpe E, García-Patos V, Vilardell-Tarrés M. Fascitis eosinofílica: estudio de 10 pacientes. Med Clin (Barc) 2005; 125(4): 145-148.